Provided by Tiger Trade Technology Pte. Ltd.

Sarepta Therapeutics

20.52
-1.5000-6.81%
Post-market: 20.51-0.0070-0.03%16:32 EDT
Volume:2.20M
Turnover:45.53M
Market Cap:2.17B
PE:-15.59
High:22.02
Open:22.02
Low:20.28
Close:22.02
52wk High:25.32
52wk Low:14.68
Shares:105.57M
Float Shares:99.05M
Volume Ratio:0.53
T/O Rate:2.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3161
EPS(LYR):-7.1300
ROE:-9.48%
ROA:-1.13%
PB:1.42
PE(LYR):-2.88

Loading ...

Jefferies says definitive readthrough to Sarepta from Novartis news ‘premature’

TIPRANKS
·
Sep 09

U.S. Stocks on the MOVE-Best Buy, Peloton, Apple

Reuters
·
Sep 09

Mizuho sees Sarepta selloff on Novartis DM1 miss as overdone

TIPRANKS
·
Sep 09

H.C. Wainwright reiterates Sell on Sarepta after Novartis study miss

TIPRANKS
·
Sep 09

U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis

Reuters
·
Sep 08

Sarepta Therapeutics Down 11.4%, Dyne Therapeutics Down 22%

THOMSON REUTERS
·
Sep 08

Sarepta Therapeutics Announces Recipients of Route 79, the Duchenne Scholarship Program, for the 2026-2027 Academic Year

THOMSON REUTERS
·
Sep 08

Sarepta, Dyne Sink After Novartis Muscle Disorder Trial Failure

Reuters
·
Sep 08

Sarepta Therapeutics Down 15.6%, Dyne Therapeutics Down 29%

THOMSON REUTERS
·
Sep 08

Shares of Some Drug Developers Fall Premarket After Novartis Late-Stage Muscle Disorder Trial Fails

THOMSON REUTERS
·
Sep 08

Novartis Twin Drug Setbacks Pile Pressure on Pipeline, CEO

Reuters
·
Sep 08

J.P. Morgan Remains a Hold on Sarepta Therapeutics (SRPT)

TIPRANKS
·
Sep 02

Sarepta to Present at Morgan Stanley Global Healthcare Conference Fireside Chat

Reuters
·
Sep 01

Sarepta Therapeutics (SRPT) Could Be 30% Undervalued After Elevidys Progress Hopes

Simply Wall St.
·
Aug 28

Sarepta Therapeutics, Inc. : JP Morgan Raises Target Price to $23 from $19

THOMSON REUTERS
·
Aug 27

Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial

Dow Jones
·
Aug 24

Trump Picks White House Adviser Heidi Overton to Run FDA, Source Says

Reuters
·
Aug 19

Evercore ISI Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)

TIPRANKS
·
Aug 10

Regenxbio Seen on Track for Duchenne Approval as Data Strengthens, RBC Says

MT Newswires Live
·
Aug 08

Sarepta Therapeutics (SRPT) Stock Rally Hinges On Profit Progress And Revenue Drop

Simply Wall St.
·
Aug 07